Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 84 people in total — 42 in each group. One group received a combination of two medicines, pembrolizumab and epacadostat, while the other group received pembrolizumab along with a placebo (an inactive substitute). The trial was measuring how often tumours shrank or disappeared (called the "objective response rate"), as well as tracking unwanted medical events (called adverse events) that participants experienced during the study. The reported data shows that, when looking at tumour response, 21.4% of participants in the pembrolizumab plus epacadostat group had their tumours shrink or disappear by a defined amount, compared with 9.5% in the pembrolizumab plus placebo group. Regarding adverse events — that is, any unwanted medical occurrences during the study — all 42 participants in the combination medicine group and 39 out of 41 participants in the placebo group experienced at least one such event. The reported data also shows that 4 participants in the combination group and 6 participants in the placebo group stopped taking their study treatment due to an adverse event. It is worth noting that this was a relatively small trial of 84 people, and the results as submitted reflect what was observed in this specific group of participants only. No conclusions about broader use should be drawn from these numbers alone. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 39054485) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Parkinson's Disease Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with a specific type of bladder or urinary tract cancer (called urothelial carcinoma) affecting the kidney, ureter, bladder, or urethra, confirmed by a lab test on a tissue sample.
- Your cancer has come back or gotten worse after receiving at least one chemotherapy treatment that included a platinum-based drug for advanced or spreading disease (certain cases where this treatment was given before or after bladder surgery may also qualify, if the cancer returned within 12 months).
- Your cancer can be measured on a scan using standard medical criteria (called RECIST v1.1).
- You are able to provide either a stored tumor tissue sample or a new tissue biopsy from a tumor that has not been treated with radiation, for testing purposes.
- You are generally able to carry out daily activities with little to no limitation (rated 0 or 1 on a standard health performance scale).
- Your heart, liver, kidneys, and other organs are functioning well enough to meet the trial's requirements.
Who may not be able to join:
- Your cancer could potentially be treated with local treatments aimed at curing it.
- You have a history of or currently have an abnormal heart rhythm reading (ECG) that the doctor considers medically significant.
- You have or have recently been treated for another type of cancer within the past 3 years.
- You currently have active cancer that has spread to the brain or the lining around the brain (though people with previously treated and stable brain metastases may still be considered — confirm with trial site).
- You have an autoimmune disease (where the immune system attacks the body) that has needed medical treatment within the last 2 years.
- You have a known history of HIV infection.
- You have a known history of, or test positive for, active hepatitis B or hepatitis C (specific blood tests are required to check this).
- You have previously used or are currently using certain medications or treatments that are not allowed under the trial's guidelines (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Mark Jones, MD, Incyte Corporation
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Objective Response Rate (ORR) With Pembrolizumab + Epacadostat Versus Pembrolizumab + Placebo
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.